Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benefits of simulation using standardized patients for training dermatology residents in breaking bad news.

Annales de dermatologie et de venereologie·2021
Same author

[Use of simulation in healthcare for therapeutic training of the parents of children with hereditary angioedema].

Annales de dermatologie et de venereologie·2020
Same author

Skills improvement after observation or direct practice of a simulated laparoscopic intervention.

Journal of gynecology obstetrics and human reproduction·2018
Same author

A retrospective study of ketamine administration and the development of acute or post-traumatic stress disorder in 274 war-wounded soldiers.

Anaesthesia·2017
Same author

Is it time to cease the single low-dose ketamine injection at induction of anesthesia?

Acta anaesthesiologica Scandinavica·2017
Same author

Autotransfusion for a haemothorax complicating an Echis pyramidum envenomation in Republic of Djibouti.

Transfusion medicine (Oxford, England)·2017

Related Experiment Video

Updated: May 20, 2026

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
08:06

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

[Parkinson's disease and ketamine]

G Mion, J-C Granry

    Annales Francaises D'Anesthesie Et De Reanimation
    |July 4, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    The 6-hydroxydopamine Rat Model of Parkinson's Disease
    08:10

    The 6-hydroxydopamine Rat Model of Parkinson's Disease

    Published on: October 27, 2021

    Related Experiment Videos

    Last Updated: May 20, 2026

    Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
    08:06

    Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

    Published on: January 15, 2010

    The 6-hydroxydopamine Rat Model of Parkinson's Disease
    08:10

    The 6-hydroxydopamine Rat Model of Parkinson's Disease

    Published on: October 27, 2021